Skip to Content

MM21-01

Main Content

Differences in outcomes on myeloma treatment worldwide.

Study #: MM21-01

Study Status: Published

Presentation(s)

2022, EBMT (Oral)
2022, ASH (Poster)
2022, ASH (Poster)

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).

Citation

Garderet L, Gras L, Koster L, Baaij L, Hamad N, Dsouza A, Estrada-Merly N, Hari P, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Mizuno S, Kawamura K, Kodera Y, Ko B, Liam C, Ho KW, Goh Ai Sim, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry Q, Alfar R, Bekadja M, Benakli M, Frutos C, Riva E, Galeano S, Bass F, Mian HS, McCurdy A, Wang FR, Meng L, Neumann D, Koh M, Snowden JA, Schönland S, McLornan DP, Hayden PJ, Sureda A, Greinix HT, Aljurf M, Atsuta Y, Niederwieser D.

American Journal of Hematology. 2024, Aug 19: (): . doi: 10.1002/ajh.27451. Epub 2024, Aug 19. PMCID:.

PubMed

PMID: 39158218

Abstract